Caroline Barbieri Blunck , Caroline Pires Poubel , Bruno A. Lopes , Thayana C. Barbosa , Ana Luiza Tardem Maciel , Elaine Sobral da Costa , Ariadne da Rocha Figueiredo , Marcelo G.P. Land , Márcia Trindade Schramm , Maura Rosane Valério Ikoma-Coltutato , Renan Garcia Gomes , Mecneide Mendes Lins , Thais Ferraz Aguiar , Marcela Braga Mansur , Mariana Emerenciano
{"title":"BCP-ALL中与IKZF1plus相关的细胞标记的特征。","authors":"Caroline Barbieri Blunck , Caroline Pires Poubel , Bruno A. Lopes , Thayana C. Barbosa , Ana Luiza Tardem Maciel , Elaine Sobral da Costa , Ariadne da Rocha Figueiredo , Marcelo G.P. Land , Márcia Trindade Schramm , Maura Rosane Valério Ikoma-Coltutato , Renan Garcia Gomes , Mecneide Mendes Lins , Thais Ferraz Aguiar , Marcela Braga Mansur , Mariana Emerenciano","doi":"10.1016/j.tranon.2024.102127","DOIUrl":null,"url":null,"abstract":"<div><div>The presence of <em>IKZF1</em> deletions has been associated with an increased relapse rate in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). There is a particular subset of <em>IKZF1</em><sup>del</sup> cases called <em>IKZF1</em><sup>plus</sup> (defined by the co-occurrence of <em>IKZF1</em><sup>del</sup> and deletions in <em>CDKN2A</em>/<em>B, PAX5</em>, or the PAR1 region, in the absence of <em>ERG</em> deletions), which is also associated with worse prognosis, but some recent studies have not found major differences between the <em>IKZF1</em><sup>del</sup> and <em>IKZF1</em><sup>plus</sup> groups. Therefore, the <em>IKZF1</em><sup>plus</sup> group still needs further comprehension and our study aims to characterise the molecular heterogeneity and identify molecular markers exclusively associated with <em>IKZF1</em><sup>plus</sup>. Two independent series of cases (TARGET, <em>n</em> = 125 and GenLAb, <em>n</em> = 60) were evaluated by segregating patients into 3 groups: <em>IKZF1</em><sup>plus</sup>, <em>IKZF1</em><sup>del</sup>, and <em>IKZF1</em><sup>wild</sup>. Differential expression analyses showed that the membrane protein-coding genes most associated with the <em>IKZF1</em><sup>plus</sup> group were: <em>KCNA5, GREB1, EPOR, SDK1</em>, and <em>PTPRB</em>. Notably, <em>KCNA5</em> and <em>GREB1</em> differential expression levels were validated in the GenLAb validation series. Regarding copy number alterations, we observed a high frequency of <em>VPREB1</em> deletions in the <em>IKZF1</em><sup>plus</sup> group, as well as additional exclusive deletions in the <em>CD200</em> and <em>BTLA</em> genes. Recent research suggests that the importance of the <em>IKZF1</em><sup>plus</sup> profile varies depending on the genetic subgroup. In this scenario, we found associations between <em>IKZF1</em><sup>plus</sup> and certain genes in BCP-ALL, being <em>KCNA5</em> and <em>GREB1</em> the most promising biomarkers for predicting <em>IKZF1</em><sup>plus</sup>. A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"50 ","pages":"Article 102127"},"PeriodicalIF":5.0000,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1936523324002547/pdfft?md5=280ef1d9a83a468a0730d31b6603c46d&pid=1-s2.0-S1936523324002547-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Characterisation of cells markers associated with IKZF1plus in BCP-ALL\",\"authors\":\"Caroline Barbieri Blunck , Caroline Pires Poubel , Bruno A. Lopes , Thayana C. Barbosa , Ana Luiza Tardem Maciel , Elaine Sobral da Costa , Ariadne da Rocha Figueiredo , Marcelo G.P. Land , Márcia Trindade Schramm , Maura Rosane Valério Ikoma-Coltutato , Renan Garcia Gomes , Mecneide Mendes Lins , Thais Ferraz Aguiar , Marcela Braga Mansur , Mariana Emerenciano\",\"doi\":\"10.1016/j.tranon.2024.102127\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The presence of <em>IKZF1</em> deletions has been associated with an increased relapse rate in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). There is a particular subset of <em>IKZF1</em><sup>del</sup> cases called <em>IKZF1</em><sup>plus</sup> (defined by the co-occurrence of <em>IKZF1</em><sup>del</sup> and deletions in <em>CDKN2A</em>/<em>B, PAX5</em>, or the PAR1 region, in the absence of <em>ERG</em> deletions), which is also associated with worse prognosis, but some recent studies have not found major differences between the <em>IKZF1</em><sup>del</sup> and <em>IKZF1</em><sup>plus</sup> groups. Therefore, the <em>IKZF1</em><sup>plus</sup> group still needs further comprehension and our study aims to characterise the molecular heterogeneity and identify molecular markers exclusively associated with <em>IKZF1</em><sup>plus</sup>. Two independent series of cases (TARGET, <em>n</em> = 125 and GenLAb, <em>n</em> = 60) were evaluated by segregating patients into 3 groups: <em>IKZF1</em><sup>plus</sup>, <em>IKZF1</em><sup>del</sup>, and <em>IKZF1</em><sup>wild</sup>. Differential expression analyses showed that the membrane protein-coding genes most associated with the <em>IKZF1</em><sup>plus</sup> group were: <em>KCNA5, GREB1, EPOR, SDK1</em>, and <em>PTPRB</em>. Notably, <em>KCNA5</em> and <em>GREB1</em> differential expression levels were validated in the GenLAb validation series. Regarding copy number alterations, we observed a high frequency of <em>VPREB1</em> deletions in the <em>IKZF1</em><sup>plus</sup> group, as well as additional exclusive deletions in the <em>CD200</em> and <em>BTLA</em> genes. Recent research suggests that the importance of the <em>IKZF1</em><sup>plus</sup> profile varies depending on the genetic subgroup. In this scenario, we found associations between <em>IKZF1</em><sup>plus</sup> and certain genes in BCP-ALL, being <em>KCNA5</em> and <em>GREB1</em> the most promising biomarkers for predicting <em>IKZF1</em><sup>plus</sup>. A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.</div></div>\",\"PeriodicalId\":48975,\"journal\":{\"name\":\"Translational Oncology\",\"volume\":\"50 \",\"pages\":\"Article 102127\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1936523324002547/pdfft?md5=280ef1d9a83a468a0730d31b6603c46d&pid=1-s2.0-S1936523324002547-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1936523324002547\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002547","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Characterisation of cells markers associated with IKZF1plus in BCP-ALL
The presence of IKZF1 deletions has been associated with an increased relapse rate in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). There is a particular subset of IKZF1del cases called IKZF1plus (defined by the co-occurrence of IKZF1del and deletions in CDKN2A/B, PAX5, or the PAR1 region, in the absence of ERG deletions), which is also associated with worse prognosis, but some recent studies have not found major differences between the IKZF1del and IKZF1plus groups. Therefore, the IKZF1plus group still needs further comprehension and our study aims to characterise the molecular heterogeneity and identify molecular markers exclusively associated with IKZF1plus. Two independent series of cases (TARGET, n = 125 and GenLAb, n = 60) were evaluated by segregating patients into 3 groups: IKZF1plus, IKZF1del, and IKZF1wild. Differential expression analyses showed that the membrane protein-coding genes most associated with the IKZF1plus group were: KCNA5, GREB1, EPOR, SDK1, and PTPRB. Notably, KCNA5 and GREB1 differential expression levels were validated in the GenLAb validation series. Regarding copy number alterations, we observed a high frequency of VPREB1 deletions in the IKZF1plus group, as well as additional exclusive deletions in the CD200 and BTLA genes. Recent research suggests that the importance of the IKZF1plus profile varies depending on the genetic subgroup. In this scenario, we found associations between IKZF1plus and certain genes in BCP-ALL, being KCNA5 and GREB1 the most promising biomarkers for predicting IKZF1plus. A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.
期刊介绍:
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.